NCT05279001

A Safety and Tolerability Study of Jaktinib

A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Detailed description

This study is a Phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of Jaktinib in patients with PMF or Post-PV/ET MF and who are relapsed/refractory to a marketed JAK inhibitor

Conditions

• Myelofibrosis

Interventions

Type	Name	Description
DRUG	Jaktinib Hydrochloride Tablet	Orally administered, twice a day

Timeline

• Start date: 2024-07-01
• Primary completion: 2025-05-31
• Completion: 2025-11-30
• First posted: 2022-03-15
• Last updated: 2024-03-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study